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Introduction
Evidence-based medicine is the cornerstone of clinical practice, but it is dependent on the
quality of evidence upon which it is based. Unfortunately, up to half of all randomized con-
trolled trials (RCTs) have never been published, and trials with statistically significant findings
are more likely to be published than those without (Dwan et al., 2013). Importantly, negative
trials face additional hurdles beyond study publication bias that can result in the disappearance
of non-significant results (Boutron et al., 2010; Dwan et al., 2013; Duyx et al., 2017). Here, we
analyze the cumulative impact of biases on apparent efficacy, and discuss possible remedies,
using the evidence base for two effective treatments for depression: antidepressants and
psychotherapy.
Reporting and citation biases
We distinguish among four major biases, although others exist: study publication bias, out-
come reporting bias, spin, and citation bias. While study publication bias involves non-
publication of an entire study, outcome reporting bias refers to non-publication of negative
outcomes within a published article or to switching the status of (non-significant) primary
and (significant) secondary outcomes (Dwan et al., 2013). Both biases pose an important
threat to the validity of meta-analyses (Kicinski, 2014).
Trials that faithfully report non-significant results will yield accurate effect size estimates,
but results interpretation can still be positively biased, which may affect apparent efficacy.
Reporting strategies that could distort the interpretation of results and mislead readers are
defined as spin (Boutron et al., 2010). Spin occurs when authors conclude that the treatment
is effective despite non-significant results on the primary outcome, for instance by focusing on
statistically significant, but secondary, analyses (e.g. instead of concluding that treatment X was
not more effective than placebo, concluding that treatment X was well tolerated and was effect-
ive in patients who had not received prior therapy). If an article has been spun, treatments are
perceived as more beneficial (Boutron et al., 2014). Finally, citation bias is an obstacle to ensur-
ing that negative findings are discoverable. Studies with positive results receive more citations
than negative studies (Duyx et al., 2017), leading to a heightened visibility of positive results.
The evidence base for antidepressants
We assembled a cohort of 105 depression trials, of which 74 were also included in a previous
study on publication bias (Turner et al., 2008); we added 31 trials of novel antidepressants
(approved after 2008) from the Food and Drug Administration (FDA) database (see online
Supplementary materials). Pharmaceutical companies must preregister all trials they intend
to use to obtain FDA approval; hence, trials with non-significant results, even if unpublished,
are still accessible.
Figure 1 demonstrates the cumulative impact of reporting and citation biases. Of 105 anti-
depressant trials, 53 (50%) trials were considered positive by the FDA and 52 (50%) were con-
sidered negative or questionable (Fig. 1a). While all but one of the positive trials (98%) were
published, only 25 (48%) of the negative trials were published. Hence, 77 trials were published,
of which 25 (32%) were negative (Fig. 1b). Ten negative trials, however, became ‘positive’ in the
published literature, by omitting unfavorable outcomes or switching the status of the primary
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and secondary outcomes (Fig. 1c). Without access to the FDA
reviews, it would not have been possible to conclude that these
trials, when analyzed according to protocol, were not positive.
Among the remaining 15 (19%) negative trials, five were pub-
lished with spin in the abstract (i.e. concluding that the treatment
was effective). For instance, one article reported non-significant
results for the primary outcome ( p = 0.10), yet concluded that
the trial ‘demonstrates an antidepressant effect for fluoxetine
that is significantly more marked than the effect produced by pla-
cebo’ (Rickels et al., 1986). Five additional articles contained mild
spin (e.g. suggesting the treatment is at least numerically better
than placebo). One article lacked an abstract, but the discussion
section concluded that there was a ‘trend for efficacy’. Hence,
only four (5%) of 77 published trials unambiguously reported
that the treatment was not more effective than placebo in that par-
ticular trial (Fig. 1d). Compounding the problem, positive trials
were cited three times as frequently as negative trials (92 v. 32
citations in Web of Science, January 2016, p < 0.001, see online
Supplementary material for further details) (Fig. 1e). Among
negative trials, those with (mild) spin in the abstract received an
average of 36 citations, while those with a clearly negative abstract
received 25 citations. While this might suggest a synergistic effect
between spin and citation biases, where negatively presented
negative studies receive especially few citations (de Vries et al.,
2016), this difference was not statistically significant ( p = 0.50),
likely due to the small sample size. Altogether, these results
show that the effects of different biases accumulate to hide non-
significant results from view.
The evidence base for psychotherapy
While the pharmaceutical industry has a financial motive for sup-
pressing unfavorable results, these biases are also present in the
other areas of research, such as psychotherapy. Without a
standardized trial registry, however, they are more difficult to
detect and disentangle. Statistical tests suggest an excess of posi-
tive findings in the psychotherapy literature, due to either study
publication bias or outcome reporting bias (Flint et al., 2015).
Of 55 National Institutes of Health-funded psychotherapy trials,
13 (24%) remained unpublished (Driessen et al., 2015), and
these had a markedly lower effect size than the published trials.
Regarding spin, 49 (35%) of 142 papers were considered nega-
tive in a recent meta-analysis (Flint et al., 2015), but we found that
only 12 (8%) abstracts concluded that psychotherapy was not
more effective than a control condition. The remaining abstracts
were either positive (73%) or mixed (19%) (e.g. concluding that
the treatment was effective for one outcome but not another).
Although we could not establish the pre-specified primary out-
come for these trials, and therefore cannot determine whether a
specific abstract is biased, published psychotherapy trials, as a
whole, clearly provide a more positive impression of the effective-
ness of psychotherapy than is justified by available evidence.
Positive psychotherapy trials were also cited nearly twice as fre-
quently as negative trials (111 citations v. 58, p = 0.003).
Negative trials with a positive or mixed abstract were cited
more often than those with a negative abstract (59 and 87 cita-
tions, respectively v. 26, p = 0.05); however, the small sample
size precludes definitive conclusions on the effects of spin on cit-
ation rates.
Preventing bias
Mandatory prospective registration has long been advocated as a
solution for study publication and outcome reporting bias. The
International Committee of Medical Journal Editors (ICMJE)
began requiring prospective registration of clinical trials as a pre-
condition for publication in 2005, but many journals do not
require registration (Knüppel et al., 2013) and others allow
Fig. 1. The cumulative impact of reporting and cit-
ation biases on the evidence base for antidepres-
sants. (a) displays the initial, complete cohort of
trials, while (b) through (e) show the cumulative
effect of biases. Each circle indicates a trial, while
the color indicates the results or the presence of
spin. Circles connected by a grey line indicate trials
that were published together in a pooled publica-
tion. In (e), the size of the circle indicates the (rela-
tive) number of citations received by that category
of studies.
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retrospective registration (Harriman and Patel, 2016). Since 2007,
the FDA also requires prospective registration of most drug trials.
This increasing pressure may explain why recently completed,
negative antidepressant trials are more frequently published
than older negative trials: all negative trials that remained unpub-
lished were completed before 2004, while the 25 trials completed
in 2004 or later (including 14 for which registration was legally
required) were all published, even though nine were negative. A
regulatory requirement is likely to be one of the most effective
measures to ensure universal registration; unfortunately, the
2007 law excludes trials of behavioral interventions (e.g. psycho-
therapy) and phase 1 (healthy volunteer) trials.
Nevertheless, registration seems insufficient to ensure com-
plete and accurate reporting of a trial. Only around half of all
trials registered at ClinicalTrials.gov were published within two
years of completion (Ross et al., 2009), and non-reporting of
protocol-specified outcomes or the silent addition of new out-
comes is also common (Jones et al., 2015, http://www.compare-
trials.org). Close examination of registries by independent
researchers may be necessary for registration to be a truly effective
deterrent to study publication and outcome reporting bias. An
alternative (or addition) to registration could be publication of
study protocols or ‘registered reports’, in which journals accept
a study for publication based on the introduction and methods,
before the results are known. Widespread adoption of this format
might also help to prevent spin, by reducing the pressure that
researchers might feel to ‘oversell’ their results to get published.
Furthermore, in our analysis, positive studies were published in
journals with a higher median impact factor (and thus higher visi-
bility) than negative studies (3.5 v. 2.4 for antidepressant trials
and 3.1 v. 2.6 for psychotherapy trials), which may be one driver
behind the difference in citation rates. Hence, adoption of regis-
tered reports might also reduce citation bias by reducing the ten-
dency for positive studies to be published in higher impact
journals. Peer reviewers could also play a crucial role in ensuring
that abstracts accurately report trial results and that important
negative studies are cited. Finally, the prevalence of spin and cit-
ation biases also shows the importance of assessing a study’s
actual results (rather than relying on the authors’ conclusions)
and of conducting independent literature searches, since reference
lists may yield a disproportionate number of positive (and posi-
tively presented) studies.
Conclusions
The problem of study publication bias is well-known. Our exam-
ination of antidepressant trials, however, shows the pernicious
cumulative effect of additional reporting and citation biases,
which together eliminated most negative results from the anti-
depressant literature and left the few published negative results
difficult to discover. These biases are unlikely to be unique to anti-
depressant trials. We have already shown that similar processes,
though more difficult to assess, occur within the psychotherapy
literature, and it seems likely that the effect of these biases accu-
mulates whenever they are present. Consequently, researchers and
clinicians across medical fields must be aware of the potential for
bias to distort apparent treatment efficacy, which poses a threat to
the practice of evidence-based medicine.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291718001873.
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